* Catalyst Biosciences Inc CBIO.OQ CBIO.O is expected
to show
a fall in quarterly revenue when it reports results on May 8
(estimated).
*
* Refinitiv's mean analyst estimate for Catalyst
Biosciences Inc
is for a loss of 10 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
This summary was machine generated May 5 at 18:35 GMT. All
figures in US dollars unless otherwise stated